And how much does hormonal suppression (HPTA shutdown) affect recovery resilience?

No published randomized, controlled BPC-157 human trials.

A canceled Phase I leaves major gaps.

Preclinical animal research vastly outweighs human research.

A few pilot clinical studies, but tiny samples.

No definitive efficacy trials in human subjects.

Human safety profile largely unverified by trials.

Existing human studies lack controls and statistical power.

Most evidence comes from rodents and lab models.

Animal healing data doesn’t guarantee human effectiveness.

Human studies reported subjective improvements, not objective results

No regulatory body has approved BPC-157 for humans.

Anecdotes aren’t clinical proof of safety or efficacy.

Ongoing or planned trials exist but not published.

Human pharmacokinetics still poorly understood today.

Claims of benefits lack rigorous human backing.